Market Cap : 60.63 B | Enterprise Value : 69.39 B | PE Ratio : 73.01 | PB Ratio : 3.51 |
---|
NYSE:BSX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BSX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Boston Scientific's current ratio for the quarter that ended in Jun. 2022 was 1.31.
Boston Scientific has a current ratio of 1.31. It generally indicates good short-term financial strength.
The historical rank and industry rank for Boston Scientific's Current Ratio or its related term are showing as below:
During the past 13 years, Boston Scientific's highest Current Ratio was 7.77. The lowest was 0.52. And the median was 1.53.
The historical data trend for Boston Scientific's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boston Scientific's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Current Ratio distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Boston Scientific's Current Ratio for the fiscal year that ended in Dec. 2021
Boston Scientific's Current Ratio for the quarter that ended in Jun. 2022 is calculated as * For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
Current Ratio (A: Dec. 2021 ) = Total Current Assets (A: Dec. 2021 ) / Total Current Liabilities (A: Dec. 2021 )
= 6317 / 4274
= 1.48
Current Ratio (Q: Jun. 2022 ) = Total Current Assets (Q: Jun. 2022 ) / Total Current Liabilities (Q: Jun. 2022 )
= 5083 / 3883
= 1.31
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Boston Scientific's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Wichmann David S | director | UNITEDHEALTH GROUP INC 9900 BREN RD E MINNETONKA MN 55343 |
Brown Vance R | officer: SVP, GC and Corp. Secretary | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Olson Scott | officer: SVP & Pres, Rhythm Management | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Scanlon Meghan | officer: SVP,Pres,Urology Pelvic Health | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Monson Jonathan | officer: VP, Corp Controller and CAO | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Fujimori Yoshiaki | director | 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
James Donna | director | ONE MIRANOVA PLACE SUITE 1040 COLUMBUS OH 43215 |
Zane Ellen M | director | C/O TUFTS-NEW ENGLAND MEDICAL CENTER 750 WASHINGTON STREET, TUFTS-NEMC #451 BOSTON MA 02111 |
Sununu John E | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Connors Nelda J | director | BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 |
Ludwig Edward J | director | C/O BECTON DICKERSON & CO 1 BECTON DR FRANKLIN LAKES NJ 07417 |
Roux David J | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Dockendorff Charles J | director | COVIDIEN LTD. 15 HAMPSHIRE STREET MANSFIELD MA 02048 |
Macmillan Stephen P | director | 250 CAMPUS DRIVE MARLBOROUGH MA 01752 |
Wang Xin Warren | officer: SVP and Pres, Asia Pacific | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
From GuruFocus
Other Sources
By tipranks.com 2022-03-03
By Seekingalpha 2022-01-31
By Zacks 2021-12-21
By Zacks 2022-01-24
By tipranks.com 2022-03-23
By Zacks 2022-02-02
By Zacks 2022-02-02
By Zacks 2021-12-23
By Zacks 2022-02-11
By Zacks 2021-10-28
By Zacks 2022-03-15
By Seekingalpha 2022-01-26
By Zacks 2021-12-21